FJ3 Stock Overview
Provides packaging materials, medical/pharmaceutical packaging materials, and materials for the functional fields in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
ZACROS Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥24.60 |
| 52 Week High | JP¥27.40 |
| 52 Week Low | JP¥22.80 |
| Beta | 0.55 |
| 11 Month Change | -3.91% |
| 3 Month Change | -6.11% |
| 1 Year Change | 6.03% |
| 33 Year Change | -13.99% |
| 5 Year Change | -14.58% |
| Change since IPO | 122.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| FJ3 | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -3.1% | -1.3% | -1.3% |
| 1Y | 6.0% | -1.6% | 7.4% |
Return vs Industry: FJ3 exceeded the German Chemicals industry which returned -1.2% over the past year.
Return vs Market: FJ3 underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| FJ3 volatility | |
|---|---|
| FJ3 Average Weekly Movement | 3.4% |
| Chemicals Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FJ3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FJ3's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1914 | 2,664 | Taku Shimoda | www.zacros.co.jp |
ZACROS Corporation provides packaging materials, medical/pharmaceutical packaging materials, and materials for the functional fields in Japan and internationally. It operates through four segments: Wellness Business, Environmental Solutions Business, Electronic Materials Business, and Industrial Infrastructure Business. The company offers wellness products, including BioPhas, a customized service that is used in single-use products for biopharmaceuticals manufacturing; MediTect IV Bag, an infusion bags; and Total Thrombus formation Analysis System, a flow chamber system.
ZACROS Corporation Fundamentals Summary
| FJ3 fundamental statistics | |
|---|---|
| Market cap | €464.05m |
| Earnings (TTM) | €29.03m |
| Revenue (TTM) | €899.55m |
16.0x
P/E Ratio0.5x
P/S RatioIs FJ3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FJ3 income statement (TTM) | |
|---|---|
| Revenue | JP¥145.69b |
| Cost of Revenue | JP¥112.71b |
| Gross Profit | JP¥32.98b |
| Other Expenses | JP¥28.28b |
| Earnings | JP¥4.70b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 252.71 |
| Gross Margin | 22.64% |
| Net Profit Margin | 3.23% |
| Debt/Equity Ratio | 1.3% |
How did FJ3 perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield17%
Payout RatioDoes FJ3 pay a reliable dividends?
See FJ3 dividend history and benchmarks| ZACROS dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Dec 02 2024 |
| Days until Ex dividend | 57 days |
| Days until Dividend pay date | 9 days |
Does FJ3 pay a reliable dividends?
See FJ3 dividend history and benchmarks